Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) for the Treatment of Children and Young Adults with Relapse or Refractory Neuroblastoma, Soft Tissue Sarcoma, Osteosarcoma, Ewing Sarcoma, and Wilms Tumor

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of autologous B7-H3 chimeric antigen receptor T cells (B7-H3CART) and how well it works in treating patients with neuroblastoma, soft tissue sarcoma, osteosarcoma, Ewing sarcoma or Wilms tumor that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Chimeric antigen receptor (CAR) T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein, such as B7-H3, on the patient’s tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving B7-H3CART may be safe, tolerable, and/or effective in treating patients with relapsed or refractory neuroblastoma, soft tissue sarcoma, osteosarcoma, Ewing sarcoma or Wilms tumors.